Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone

被引:54
|
作者
King, AE
Morgan, K
Sallenave, JM
Kelly, RW
机构
[1] Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland
[2] Univ Edinburgh, Sch Med, MRC, Rayne Lab,Ctr Inflammat Res, Edinburgh EH8 9AG, Midlothian, Scotland
关键词
elafin; progesterone; reproductive; secretory leukocyte protease inhibitor; T47D cell line;
D O I
10.1016/j.bbrc.2003.08.151
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Elafin and secretory leukocyte protease inhibitor (SLPI) are anti-protease and anti-microbial molecules present at mucosal surfaces. Both molecules are expressed in the female reproductive tract where they may be involved in innate immune defence. This study examines the role of progesterone in the regulation of SLPI and elafin. Progesterone treatment increases expression of SLPI mRNA and protein in the T47D breast epithelial cell line and this upregulation is attenuated in the presence of the anti-gestogens, RU486 and ZK98734, confirming the involvement of the nuclear progesterone receptor. A putative progesterone response element has been identified in the SLPI promoter. Progesterone also acts in synergy with the proinflammatory cytokines, IL-1beta and TNFalpha, to increase SLPI. In contrast, progesterone treatment has no direct effect on elafin mRNA expression. In summary, progesterone has a differential effect on SLPI and elafin expression and although both vary within the uterus throughout the menstrual cycle, progesterone is likely to contribute to the direct regulation of SLPI in the female reproductive tract even in the presence of inflammatory agents. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:594 / 599
页数:6
相关论文
共 50 条
  • [21] Expression of secretory leukocyte protease inhibitor in women with endometriosis
    Suzumori, N
    Sato, M
    Yoneda, T
    Ozaki, Y
    Takagi, H
    Suzumori, K
    FERTILITY AND STERILITY, 1999, 72 (05) : 857 - 867
  • [22] Secretory leukocyte protease inhibitor - an endogenous antimicrobial agent
    Wahl, SM
    AIDS, 2001, 15 : S54 - S54
  • [23] Characterization of secretory leukocyte protease inhibitor as an inhibitor of implantation serine proteinases
    Sharma, Navneet
    Kaur, Jaspreet
    Xu, Hui
    zur Nieden, Nicole
    Rancourt, Derrick
    MOLECULAR REPRODUCTION AND DEVELOPMENT, 2008, 75 (07) : 1136 - 1142
  • [24] THE EFFECT OF THE SECRETORY LEUKOCYTE PROTEASE INHIBITOR ON LEUKOCYTE PROTEASES RELEASED DURING PHAGOCYTOSIS
    AXELSSON, L
    LINDER, C
    OHLSSON, K
    ROSENGREN, M
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1988, 369 (05): : 89 - 93
  • [25] Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema
    Betsuyaku, T
    Takeyabu, K
    Tanino, M
    Nishimura, M
    EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (06) : 1051 - 1057
  • [26] INTERACTION OF SECRETORY LEUKOCYTE PROTEASE INHIBITOR WITH PROTEINASE-3
    RAO, NV
    MARSHALL, BC
    GRAY, BH
    HOIDAL, JR
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 8 (06) : 612 - 616
  • [27] Overexpression of secretory leukocyte protease inhibitor promotes the invasion of cholangiocarcinoma
    Jantra, Jeranan
    Kumphune, Sarawut
    Tohtong, Rutiwan
    Wongkham, Sopit
    Phimsen, Suchada
    CANCER SCIENCE, 2018, 109 : 1383 - 1383
  • [28] Activity of secretory leukocyte protease inhibitor in salivary secretions.
    Shugars, DC
    Fu, K
    Alexander, AA
    Patton, LL
    JOURNAL OF DENTAL RESEARCH, 1998, 77 : 880 - 880
  • [29] Salivary secretory leukocyte protease inhibitor increases in HIV infection
    Lin, AL
    Johnson, DA
    Stephan, KT
    Yeh, CK
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2004, 33 (07) : 410 - 416
  • [30] LARGE-SCALE REFOLDING OF SECRETORY LEUKOCYTE PROTEASE INHIBITOR
    SEELY, RJ
    YOUNG, MD
    ACS SYMPOSIUM SERIES, 1991, 470 : 206 - 216